Uncategorized
Expert Talk on ” A unique target for managing proinflammatory response in different immunological disorders”
Ask Your Questions to our Experts
Anifrolumab Shows Durable Benefits in Achieving LLDAS and Remission in SLE: TULIP and Extension Trial Outcomes
Long-term treatment with anifrolumab significantly increased the likelihood of achieving lupus low disease activity state (LLDAS) and remission as defined by the DORIS criteria in …
New research reveals speckled and homogeneous patterns of antinuclear antibodies in rheumatoid arthritis
A recent study published in the Journal of Clinical Medicine has uncovered important associations between antinuclear antibodies (ANA) and clinical outcomes in rheumatoid arthritis (RA) …
E74-like factor 1 identified as a promising biomarker for systemic lupus erythematosus
A recent study published in Human Molecular Genetics has spotlighted E74-like factor 1 (ELF1) as a potential biomarker for disease activity and renal involvement in …
Genetic study unveils the association between gut bacteria and elevated risk of ankylosing spondylitis
A groundbreaking study published in PLOS ONE has revealed a potential bidirectional link between gut microbiota and ankylosing spondylitis (AS), providing new insights into the …
Breakthrough in Sjogren’s disease: Phase 2 trial reveals efficacy of dazodalibep
In a significant advancement for the treatment of Sjögren’s disease (SjD), a phase 2 clinical trial published in Nature Medicine has demonstrated the efficacy of …
Breakthrough discovery: Targeting PGAM5 in macrophages could revolutionize osteoarthritis treatment
In a groundbreaking study, researchers have identified a significant increase in phosphoglycerate mutase 5 (PGAM5) in macrophages within osteoarthritic (OA) synovium compared to controls. This …